Corbus Pharmaceuticals Holdings, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $49.02 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $42.00, a 11.11% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $37.80, a 64.71% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $107.10, a 12500.00% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.85, a 82.11% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $47.83, a 50.10% decline from fiscal 2024.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $95.86, a 34.69% decline from fiscal 2023.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $146.78, a 11.86% decline from fiscal 2022.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $166.53, a 20.36% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $49.02 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $42.00 10-Q · filed 2026-05-12 | ||||
| 2025-12-31 | $47.83 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $47.83 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | $37.80 10-Q · filed 2025-08-05 | ||||
| 2025-03-31 | $37.80 10-Q · filed 2025-05-06 | ||||
| 2024-12-31 | $95.86 10-K · filed 2025-03-11 | ||||
| 2024-09-30 | $70.73 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $70.73 10-Q · filed 2024-08-06 | ||||
| 2024-03-31 | $107.10 10-Q · filed 2024-05-07 | ||||
| 2023-12-31 | $146.78 10-K · filed 2024-03-12 | ||||
| 2023-09-30 | $3.18 10-Q · filed 2023-11-07 | ||||
| 2023-06-30 | $0.85 10-Q · filed 2023-08-08 | ||||
| 2023-03-31 | $0.85 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | $166.53 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | $4.34 10-Q · filed 2022-11-08 | ||||
| 2022-06-30 | $4.75 10-Q · filed 2022-08-09 | ||||
| 2022-03-31 | $4.75 10-Q · filed 2022-05-10 | ||||
| 2021-12-31 | $209.10 10-K · filed 2023-03-07 | $6.97 10-K · filed 2022-03-08 | |||
| 2021-09-30 | $0.11 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |